Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. - Wikidata - wikimedia - TriplyDB

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry.

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry.

http://www.wikidata.org/entity/Q34243582

about

Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats Early chronic obstructive pulmonary disease: definition, assessment, and prevention Quantitative computed tomography imaging in chronic obstructive pulmonary disease Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity Fifty years on: GWAS confirms the role of a rare variant in lung disease.Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.A novel model and molecular therapy for Z alpha-1 antitrypsin deficiency.Quantitative computed tomography in chronic obstructive pulmonary disease A review of augmentation therapy for alpha-1 antitrypsin deficiency.α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes.α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism Does augmentation with alpha1-antitrypsin affect neutrophil extracellular traps formation?Phenotyping of chronic obstructive pulmonary disease using the modified Bhalla scoring system for high-resolution computed tomography.Alpha1-antitrypsin deficiency: a clinical-genetic overview.Disorders of protein misfolding: alpha-1-antitrypsin deficiency as prototype.Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis.The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency.Quantitative computed tomography in COPD: possibilities and limitations.Neutrophil elastase-mediated lung disease.Recent advances in α-1-antitrypsin deficiency-related lung disease.Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.Using pulmonary imaging to move chronic obstructive pulmonary disease beyond FEV1.Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease: A Family Perspective.The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials.Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.Standardizing CT lung density measure across scanner manufacturers.Lung Mass in Smokers.The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with COPD.Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature.

P2860

Q22306038-E321AC6F-5364-4C67-804E-3BB09280C1D7 Q26858837-91D264D9-3C70-4392-AB15-501605B451F8 Q26998557-EB8924CB-820A-430C-A9ED-D657C9DFC0DE Q28067775-837AC0AD-FDFD-41CF-A9B2-9D8659A320EC Q28080450-D2E12336-801B-41A5-B5D6-FBE452D6B1ED Q28385458-99308D3A-084C-4212-9A48-4451630FA159 Q28392320-F3F82A1E-6538-4B81-A0AA-A39F5AE5677B Q28728578-7518EF2F-EDA9-4931-B65D-6180C240B8E0 Q31130026-4F7A205D-F4CF-4580-84BD-CC222BC937BB Q33743024-001AD8A9-C905-493C-8D9F-165EA28CD7CA Q34072799-EA1B2924-5E11-4E0E-9262-5D6C251EE761 Q34166577-B978462F-9867-4559-9A02-093CC2F4A868 Q34268108-AC13BCAF-0D4E-42B6-8680-E73562D94051 Q34428735-BA39CBE0-F2AC-42D8-AF69-23FEE96B4540 Q34540664-BEFB951C-B91B-4B4D-9146-DC445E2B10C8 Q34980209-6E0F5C3B-46C8-486A-8E08-C7C25648C626 Q35031693-3B3CB964-E1E1-4988-A446-26A66A223E45 Q35063726-ABBC2BED-0307-4AFC-81BF-9EC7F6E31D6F Q35115856-57D9B19F-4898-47FE-A7E7-9C70210AEF5A Q35233352-AB821BE4-4C45-442B-8F5E-5F8A81EA0068 Q35596461-0DCD2C9F-D705-4786-96A0-5B15BD4BCADA Q36170894-6E0162F4-FCB3-44B7-933A-894F2D55C3D4 Q36777597-15D32208-EC3A-429B-A955-5B6075983211 Q36925199-8D3B59F5-04B3-4959-A29E-1E56B2BD5EEC Q37049924-8309BD6C-5877-4A47-B2F7-2F8152DF329E Q37173117-ABDF89A8-468D-4D3E-8B2E-AA75EBCD3761 Q37362027-0ABC1A84-C14E-4AF3-A1E5-6052B3599A52 Q37894093-75BAB159-506F-40BD-8910-F86DB729BC1D Q37969650-08B371D3-CA4B-42A9-8460-F4290FB69CE0 Q38092892-A4505CAB-E9D0-471B-B867-09A94BB46890 Q38111790-EC3C1BBF-7057-4A9D-9BAF-EAB3719A8E30 Q38114852-CE4574E1-0F01-4713-8FE7-BE7F355AF60D Q38215807-D1D16A16-485F-459D-A6B4-D7CDF4BAD6EB Q38283014-0567C24C-3BF1-4BA4-AF9A-29D821D9FC61 Q38604616-1CC707B6-C82B-4426-BD02-4B98ED1706DF Q38832928-B9C88B4C-6EB4-4A85-A6DF-A71E654C58AA Q39036009-80564C31-8F53-4E39-9160-54491B4C3D3A Q39112080-08B5B44E-0DFB-449E-8417-0EB9EC1FC7A7 Q39404790-12204322-6748-4CBC-A203-89ABDB2B1A64 Q41138327-D300FA93-3A57-41A0-B84E-4BDDA5D7C31C

P2860

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry.

http://www.wikidata.org/entity/Q34243582

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@ast

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@en

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@nl

type

label

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@ast

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@en

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@nl

prefLabel

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@ast

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@en

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@nl

P1433

Q34243582-CED02A39-80E2-4F0C-A565-7D3D85B6B92E

P1476

Q34243582-A4A4841A-65A1-442C-9289-662DE19D788E

P2093

Q34243582-229CDBFC-0E05-4BB4-8B41-8E6DE54865DA

Q34243582-685B838F-D3B7-48F5-806A-39F695B5983D

Q34243582-7E8B2435-571C-4A7C-B223-E8A6199B3238

Q34243582-B36C3F8D-39FD-47AB-B184-D5E984EB937C

Q34243582-B96D2CAB-94D8-4682-835B-1B52E2EC6CA8

Q34243582-ED3022EB-AB35-4AD9-9232-DC1E2AEE747C

P2860

Q34243582-05E142B0-B4CA-4A44-AF4F-9C37C802F76C

Q34243582-07145AA4-4D42-4D4F-B9DB-BB69DF8BB72E

Q34243582-0B0AA936-8C0C-4DD7-B21B-63C05093C212

Q34243582-113DCF74-DFAE-4255-AF36-66AE6560BD9B

Q34243582-1B13F8CE-4BA6-4FFD-87F1-5AA5D8113231

Q34243582-1E3CB982-0467-4B1C-B730-6E65FA644FF7

Q34243582-2C72F46E-ABC6-4088-A7F7-3EBEE5952C0D

Q34243582-3A0E0EFE-9308-41D7-9FB5-1D2864530524

Q34243582-41C87FBB-3280-4198-AFFC-22B671ED7C9C

Q34243582-487140F9-9F70-47B3-A77F-8483FDD3E882

P2888

Q34243582-5A6657FB-686C-43B4-AFAE-EB6764E61B0E

P304

Q34243582-94D14EAC-6A09-4609-BA90-E0BBFA0C48A4

P31

Q34243582-CEDF3EDB-3C84-4978-B507-A9A7AD3C0D80

P356

Q34243582-BC19AB5B-40B8-4DD6-BE8F-9ACED108CE5E

P478

Q34243582-9988BBF3-C830-4186-988D-F9A94BCFDC3E

P577

Q34243582-93154AF5-4AB1-4395-A6CF-3FA82CDB51C7

P5875

Q34243582-60D7C8A0-29FF-4CCA-ACC9-6DF98AD8670A

P6179

Q34243582-DC135CEE-7CBF-4A95-A9AD-965A6F05F023

P698

Q34243582-DFDEACDF-2E99-4170-BEAC-945AB9AC4683

P932

Q34243582-5F31992F-1182-4C91-B72D-E717DB369660

P356

1465-9921-11-136

P1433

Respiratory Research

P1476

Therapeutic efficacy of α-1 an ...... puted tomography densitometry.

@en

P2093

Asger Dirksen

http://www.w3.org/2001/XMLSchema#string

Berend C Stoel

http://www.w3.org/2001/XMLSchema#string

David G Parr

http://www.w3.org/2001/XMLSchema#string

Eeva Piitulainen

http://www.w3.org/2001/XMLSchema#string

Jan Stolk

http://www.w3.org/2001/XMLSchema#string

Robert A Stockley

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Meta-analysis of individual participant data: rationale, conduct, and reporting.

Meta-analysis of the literature or of individual patient data: is there a difference?

Scales to assess the quality of randomized controlled trials: a systematic review.

Predictors of mortality in alpha1-antitrypsin deficiency

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency.

Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease.

Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.

Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.

P2888

1465-9921-11-136

P304

136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1465-9921-11-136

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47335585

http://www.w3.org/2001/XMLSchema#string

P6179

1051632341

http://www.w3.org/2001/XMLSchema#string

P698

20920370

http://www.w3.org/2001/XMLSchema#string

P932

2964614

http://www.w3.org/2001/XMLSchema#string